文献速递心境障碍

斯坦福神经调控疗法治疗难治性抑郁:随机对照试验证实疗效及脑电机制与预测标志物

Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy.
PubMed 文献 · World Psychiatry · 2026-01-01

一项双盲假对照随机对照试验纳入53例难治性抑郁患者,48例随机接受活性(N=24)或假(N=24)斯坦福神经调控疗法(SNT)。治疗1个月时活性组缓解率50.0%高于假组20.8%(p=0.035),应答率54.2%高于25.0%(p=0.039),并发现左侧前扣带回beta功率与疗效相关。

要点

  • SNT治疗1个月缓解率50.0%优于假刺激20.8%,应答率54.2%优于25.0%。
  • 活性SNT后额叶beta功率下降,假刺激无此变化,两项试验结果一致。
  • 基线左前扣带回beta功率较高者从活性SNT获益更大,或为预测标志物。

核心结论

  • 本研究重复证实SNT对难治性抑郁具有快速疗效,并提示左侧额叶beta抑制可能是其作用机制,基线左前扣带回beta功率为候选预测标志物。

研究设计与样本

  • 双盲假对照随机对照试验,纳入53例难治性抑郁患者,48例符合入组标准者随机分为活性SNT组(N=24)与假SNT组(N=24),并结合初始与当前试验的脑电数据。

主要发现

  • 治疗1个月缓解率活性组50.0% vs 假组20.8%(χ2 1,48=4.5,p=0.035),应答率54.2% vs 25.0%(χ2 1,48=4.3,p=0.039)。
  • 活性SNT后额叶beta功率显著下降,假刺激无此变化,两项试验结果一致。
  • 活性SNT后左前扣带回beta功率下降越大,临床改善越好(即刻rho=0.48,p=0.019;1个月rho=0.51,p=0.012)。
  • 基线左前扣带回beta功率越高,活性SNT后获益越大(即刻β=-10.26,p=0.0042;1个月β=-9.00,p=0.024),假刺激未见此关联。

关键数值与推荐

  • 缓解率:活性SNT 50.0% vs 假SNT 20.8%(χ2 1,48=4.5,p=0.035)。
  • 应答率:活性SNT 54.2% vs 假SNT 25.0%(χ2 1,48=4.3,p=0.039)。
  • 左前扣带回beta功率变化与即刻临床改善相关(rho=0.48,p=0.019),与1个月改善相关(rho=0.51,p=0.012)。
  • 基线左前扣带回beta功率预测即刻获益(β=-10.26,p=0.0042)与1个月获益(β=-9.00,p=0.024)。

临床怎么用

  • SNT可作为难治性抑郁的快速起效神经调控选择,临床可结合基线左前扣带回beta功率评估获益可能性,并用脑电beta变化监测疗效。

局限性

  • 本研究样本量较小(48例随机),脑电机制与预测标志物结果需更大样本验证,SNT的长期疗效与安全性未在本文报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stanford neuromodulation therapy (SNT) is a rapid-acting, high-dose, intermittent theta-burst stimulation protocol. Although it has previously demonstrated efficacy for treatment-resistant depression (TRD) in a randomized controlled trial (RCT), replication in a larger sample is needed. Additionally, the electrophysiological effects of SNT remain unknown. Here we report results from a new double-blind, sham-controlled RCT along with electroencephalography (EEG) findings from the initial and current trials. In the current RCT, 53 participants with TRD were enrolled, and 48 who continued to meet entry criteria were randomized to receive active (N=24) or sham (N=24) SNT. At 1-month, remission (primary outcome) was achieved in 50.0% of active vs. 20.8% of sham participants (χ2 1,48=4.5, p=0.035), and response (secondary outcome) similarly favored active treatment (54.2% vs. 25.0%; χ2 1,48=4.3, p=0.039). Beta band EEG findings converged across trials: frontal beta power decreased significantly following active but not sham SNT in both the initial pilot study and the current trial. Additionally, beta baseline activity and post-SNT changes related to treatment efficacy in the current study. Specifically, greater post-SNT reduction in left anterior cingulate cortex (L-ACC) beta power correlated with greater clinical improvement immediately (rho=0.48, p=0.019) and 1-month after (rho=0.51, p=0.012) active SNT. Moreover, higher pre-treatment L-ACC beta power predicted greater subsequent clinical benefit from active SNT (immediate-post: β=-10.26, p=0.0042; 1-month after: β=-9.00, p=0.024). Neither of these L-ACC beta power findings was observed with sham stimulation. In sum, this study replicates SNT's therapeutic efficacy, identifies left frontal beta suppression as a potential mechanism of action, and highlights baseline L-ACC beta power as a candidate scalable pre-treatment biomarker of efficacy.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kratter IH, Austelle CW, Lissemore JI, et al. Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy. World Psychiatry. 2026. PMID: 41536095. doi:10.1002/wps.70032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。